Related Experiment Video
Updated: Jun 1, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Preliminary experiences in treating infantile hemangioma with propranolol
Qiang Chai1, Wei-liang Chen, Zhi-quan Huang
1From the Department of Oral and Maxillofacial Surgery, Sun Yet-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Abstract:
The aim of this study was to evaluate the outcome of treating infantile hemangioma with the use of oral propranolol. A total of 27 patients with hemangiomas were treated with oral propranolol therapy. The subjects included 21 female patients and 6 male patients whose age ranged between 3 weeks and 7 months. Locations of lesions were as follows: 22 on the face and neck, 3 on the trunk, and 2 on the limbs. The dose of 0.5 mg/kg/d of propranolol was administered; and was gradually doubled to a maximum of 2 mg/kg/d. The treatment lasted for a period of 2.75 to 5.75 months without major complications. Two days later, a change in color was observed in 100% of patients, and 2 weeks later >75% reduction in diameter of the original lesion was found in 25.9% of patients. Treating infantile hemangioma with the use of oral propranolol is effective and reliable.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
